<The fellow who opened this thread on 8.6.97 gives the I.P.O. at $12-$14!>
Barely 2 years ago!
"Our core bisiness is the development of biopharmaceuticals using our proprietary rare genes as a foundations"
"During 98'&99', we announced three potential product candidates: IL-1Hy, anti-inflammatory, DDF potential vaccine producing reagent, and CD39 family, potential cardiovascular anti-clotting products."
"98' was also a year of progress for our HyChip products as we completed development, began production and introduced the HyChip Early Access Program with PE Corp"
"Our overall goal is to have a steady flow of revenues from HyProfile genes and their products and HyChip products in various stages of development".... ""The HyChip system utilizes arrays of completee set of DNA probes, in conjunction with a target-specific cocktail of labeled probes, to identify differences between a referennce and test sample. One major advantage of the HyChip systemm is that, since the chip contains all possible probes, it can be used to sequence DNA from any source." "The Chip is therefor Universal, only one chip is needed for a wide variety of targets... other existing DNA chip technologies require previous knowlege of the sequence and the mutations to design the chips and at least one chip has to be made for each gene."
Company is burning cash rapildy at this point... it's not clear to me how much of this is non-recurring. Chirons 'deal is 5.5mill per year and runs out this next May... The PE deal is several more years, doesn't say annual pymts... PE owns the "chip system" while HYSQ owns the "chip"... the chips are used by PE. PE bought $5 worth of stock @ IPO price & CHIR bought 1/2 that.
Hope this helps... I'm interested as well in others take, WS certainly has annointed king AFFX in the biochip race and decided the others are worthless, I don't think that makes sense. Other than that, I know nothing. Own a "smidge"... think I'll buy more as well, cheap shot with the others flying away.
DAK |
